Novozymes revenue and financials

NSIS.B · Nasdaq Copenhagen · DKK

Compare Novozymes
kr 451.40Change from previous close: +0.18%Absolute change: +kr 0.80

Close · November 17, 2026

In the fiscal year ended December 2025, Novozymes reported revenue of €4.16B (+8.45% year over year). Net income was €583.6M, a net margin of 14.0%.

Annual revenue · 2025: €4.16B
  1. €1.9B2016
  2. €1.95B2017
  3. €1.93B2018
  4. €1.92B2019
  5. €1.88B2020
  6. €2.01B2021
  7. €2.36B2022
  8. €2.4B2023
  9. €3.83B2024
  10. €4.16B2025

Fiscal year ending in December. Sources and method on the page How we analyse stocks.

At a glance

Revenue growth
+8.45%
2025 vs 2024
Net income growth
+90.84%
2025 vs 2024
Net margin
14.0%
2024: 8.0%

How Novozymes is changing

Calculated from the annual statements; each fiscal year is labelled with the year it ends.

Financial data

Amounts in millions of EUR; per-share values in EUR; shares in millions.

Income statement · Annual
Item2025202420232022202120202019201820172016
Total revenue4,1583,8342,4022,3602,0101,8831,9251,9271,9521,904
Cost of revenue1,8521,8401,0971,071849828855815820804
Gross profit2,3051,9931,3051,2891,1611,0551,0691,1111,1321,099
Selling, general and administrative912766446430380309329313332325
Research and development449413271267266256263248255251
Operating income962843611602523492480557553539
EBIT962843611602523492480557553539
EBITDA1,5371,387797769680632614683683663
Interest expense68.376.46.513.713.78.511.51.73.64.2
Pre-tax income743417525613527473509527521522
Income tax16011111711710593.486.294.9102112
Net income584306406494423380422432419411
Net income to common shareholders584306406494423380422432419411
Basic EPS1.251.101.471.791.521.351.481.491.421.37
Diluted EPS1.250.671.461.771.511.351.471.481.411.35
Average shares (basic)467278276277278280285290295300
Average shares (diluted)467278278279280282287292297303
Dividend per share0.870.83—0.810.740.710.700.670.600.54

Companies in the group: same industry, similar size